Its flagship product, Livmarli (maralixibat), is approved for treating cholestatic pruritus in pediatric ALGS patients, contributing to the company’s revenue. Vivet Therapeutics collaborates ...
Morgan Stanley upgraded Takeda (TAK) to Overweight from Equal Weight with a price target of 5,500 yen, up from 4,300 yen. The company does not ...
Canada announced that Health Canada has expanded the marketing authorization for HyQvia for chronic inflammatory demyelinating polyneuropathy as maintenance therapy after stabilization with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback